The stock has been halted and awaits being reopened
The FDA has approved Biogen’s Alzheimer drug Aducanumab using an accelerated approval pathway. The FDA does require Biogen to conduct a postapproval clinical trial and said that they can take away the approval upon unfavorable results.
This article was originally published by Forexlive.com. Read the original article here.